This PR sums up

New Post Public Reply Private Reply Replies (0) Message Board
joey68
735
This PR sums up DCTH:

http://delcath.com/reuters-news/?id=2262473

1. DCTH's product has been in use for years in Europe and is doing well:

The product is commercially available in Europe under the trade name CHEMOSAT, and is being evaluated as an investigational therapy in the U.S. Delcath is currently enrolling patients in the FOCUS trial, a global Phase 3 clinical trial that is investigating PHP with Melphalan/HDS as a treatment for patients with ocular melanoma that has metastasized to the liver.

2. This is what it does:

PHP is a minimally invasive procedure that isolates the liver from the body’s circulatory system, so that a high dose of chemotherapy (melphalan hydrochloride) may be infused directly into the liver with the potential to treat both visualized and non-visualized metastases. Blood from the liver is then filtered to remove the chemotherapeutic agent thereby minimizing systemic exposure and potentially the associated side effects.

3. It works:

In the case of Mr. Carney, he was referred to Spire Southampton, and received his first PHP treatment in December 2013. In the intervening period, he has also undergone liver resections and immunotherapy treatments. He recently became the first patient in the world to receive eight PHP treatments, which controlled the tumor and allowed him to conduct normal daily activities at his home.

4. Phase 3 trial in effect for USA:

We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

Delcath Systems Inc. (DCTH) Stock Research Links

DCTH Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Tryg's Recent Share Buyback Transactions Explained

Updated Category News Views 300

Understanding Tryg's Share Buyback Program Tryg A/S has made headlines with its recent announcement regarding a significant share buyback program. This initiative reflects the company's strategic approach to enhancing shareholder value. Announced on December 4th, Tryg has committed to a buyback program valued at up to DKK 2.0 billion and operates under the guidelines set...

Continue Reading
2026 Travel Trends Unveiled: A Curated Experience Awaits

Updated Category News Views 206

Skyscanner's Insightful Travel Trends for 2026 As we look toward 2026, travelers are set to embrace a new era of journeys, one that focuses on personal experiences and purposeful travel. From exploring culinary delights to engaging with local cultures, here are the seven trends transforming the way people explore the world. Embracing Beauty Rituals on the Road Travelers...

Continue Reading
Nvidia's Strong Earnings: What to Expect for Future Growth

Updated Category News Views 229

Nvidia's earnings were turning heads back in 2024, when the stock was on fire. It had shot up a jaw-dropping 172% year-to-date after an insane 239% hike the previous year. Traders knew this wasn't just luck; it was about consistently beating analyst expectations and fueling investor excitement. Nvidia Earnings: A History of Beats Historically, firms in the S&P 500 tend to...

Continue Reading
Electric Rays and Their Unique Defense Against Sharks

Updated Category News Views 174

Electric Rays’ Surprising Defense Mechanism Recent research has revealed that electric rays employ a remarkable defense strategy against predators, particularly sharks. These creatures are not only bold in their approach but also possess a unique ability to generate electric discharges that they utilize to ward off threats in their environment. Understanding the...

Continue Reading
A Look at Reinsurance Group's Remarkable Growth Over 5 Years

Updated Category News Views 325

Understanding the Growth of Reinsurance Group Over the past five years, Reinsurance Group of America Inc (NYSE: RGA) has significantly outshined the market, achieving an impressive annualized outperformance of 3.25%. This translates into an attractive average annual return of 17.93%, which illustrates the company’s solid position within the finance sector. What Would a...

Continue Reading